Study on Chemoradiotherapy for Lung Cancer
Author Information
Author(s): Segawa Y, Ueoka H, Kiura K, Kamei H, Tabata M, Sakae K, Hiraki Y, Kawahara S, Eguchi K, Hiraki S, Harada for the Okayama Lung Cancer Study Group
Primary Institution: National Shikoku Cancer Center Hospital
Hypothesis
Can a combination of cisplatin and 5-fluorouracil with concurrent hyperfractionated thoracic radiation provide a more effective treatment for locally advanced non-small-cell lung cancer?
Conclusion
The combination of cisplatin and 5-FU with concurrent hyperfractionated thoracic radiation is effective for treating locally advanced unresectable non-small-cell lung cancer.
Supporting Evidence
- 74% of patients responded to the treatment.
- Median survival time was 18.7 months.
- 66% survival rate at 1 year.
Takeaway
This study tested a new treatment for lung cancer and found that it helped many patients live longer.
Methodology
Patients received three cycles of cisplatin and 5-FU along with hyperfractionated thoracic radiation over a period of time.
Potential Biases
Potential bias due to lack of randomization and small sample size.
Limitations
The study had a small sample size and was not randomized.
Participant Demographics
Patients were previously untreated with locally advanced unresectable NSCLC, aged ≤ 75 years, and with performance status ≤ 2.
Statistical Information
P-Value
0.007
Statistical Significance
p=0.007
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website